Patents by Inventor K. Roger Aoki

K. Roger Aoki has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment of pain
    Patent number: 9072736
    Abstract: Use of a therapeutic molecule, for the treatment of specific pain conditions, wherein the therapeutic molecule is a single chain, polypeptide fusion protein, comprising: a non-cytotoxic protease, or a fragment thereof, which protease or protease fragment can cleave a protein of the exocytic fusion apparatus of a nociceptive sensory afferent; a Targeting Moiety that can bind to a Binding Site on the nociceptive sensory afferent, which Binding Site can undergo endocytosis to be incorporated into an endosome within the nociceptive sensory afferent; a protease cleavage site at which site the fusion protein is cleavable by a protease, wherein the protease cleavage site is located between the non-cytotoxic protease or fragment thereof and the Targeting Moiety; and a translation domain that can translocate the protease or protease fragment from within an endosome, across the endosomal membrane and into the cytosol of the nociceptive sensory afferent.
    Type: Grant
    Filed: January 27, 2012
    Date of Patent: July 7, 2015
    Assignees: Allergan, Inc., Syntaxin Limited
    Inventors: Keith Foster, John Chaddock, Philip Marks, Patrick Stancombe, K. Roger Aoki, Joseph Francis, Lance Steward
  • Reduction Of Antibody Response Against Botulinum Neurotoxin And Variants Thereof
    Publication number: 20130330369
    Abstract: The present invention provides a method of tolerizing a subject to botulinum toxin and botulinum toxin variants.
    Type: Application
    Filed: October 7, 2011
    Publication date: December 12, 2013
    Applicant: Allergan, Inc.
    Inventors: M. Zouhair Atassi, Behzod Z. Dolimbek, K. Roger Aoki
  • Botulinum toxin treatments
    Patent number: 8486886
    Abstract: A method and composition for treating a patient suffering from a disease, disorder or condition and associated pain include the administration to the patient of a therapeutically effective amount of a neurotoxin selected from a group consisting of Botulinum toxin types A, B, C, D, E, F and G.
    Type: Grant
    Filed: May 22, 2012
    Date of Patent: July 16, 2013
    Assignee: Allergan, Inc.
    Inventors: K. Roger Aoki, Michael W. Grayston, Stephen R. Carlson, Judith M. Leon
  • BOTULINUM TOXIN TREATMENTS
    Publication number: 20120232022
    Abstract: A method and composition for treating a patient suffering from a disease, disorder or condition and associated pain include the administration to the patient of a therapeutically effective amount of a neurotoxin selected from a group consisting of Botulinum toxin types A, B, C, D, E, F and G.
    Type: Application
    Filed: May 22, 2012
    Publication date: September 13, 2012
    Applicant: ALLERGAN INC.
    Inventors: K. Roger AOKI, Michael W. Grayston, Steven R. Carlson, Judith M. Leon
  • Post-translational modifications and clostridial neurotoxins
    Patent number: 8119767
    Abstract: The present invention discloses modified neurotoxins with altered biological persistence. In one embodiment, the modified neurotoxins are derived from Clostridial botulinum toxins. Such modified neurotoxins may be employed in treating various conditions, including but not limited to muscular disorders, hyperhidrosis, and pain.
    Type: Grant
    Filed: January 17, 2007
    Date of Patent: February 21, 2012
    Assignee: Allergan, Inc.
    Inventors: Lance E. Steward, Ester Fernandez-Salas, Athena Spanoyannis, K. Roger Aoki, Wei-Jen Lin
  • Use of the neurotoxic component of a botulinum toxin for treating arthritis
    Patent number: 8052980
    Abstract: A method for treating a patient suffering from arthritis and associated pain include the administration to the patient of a therapeutically effective amount of a neurotoxic component of neurotoxin selected from a group consisting of Botulinum toxin types A, B, C, D, E, F and G.
    Type: Grant
    Filed: August 28, 2009
    Date of Patent: November 8, 2011
    Assignee: Allergan, Inc.
    Inventors: K. Roger Aoki, Michael W. Grayston, Steven R. Carlson, Judith M. Leon
  • Chimera botulinum toxin type E
    Patent number: 8017741
    Abstract: The present invention relates to a toxin comprising a modified light chain of a botulinum toxin type E, wherein the modified light chain comprises amino acid sequence PFVNKQFN (SEQ ID NO: 120) at the N-terminus, and amino acid sequence xDxxxLL (SEQ ID NO: 111) at the C-terminus, wherein x is any amino acid.
    Type: Grant
    Filed: January 8, 2010
    Date of Patent: September 13, 2011
    Inventors: Ester Fernandez-Salas, Lance E. Steward, Todd Herrington, K. Roger Aoki
  • Nucleic acids encoding chimera botulinum toxin type E
    Patent number: 8008465
    Abstract: The present invention relates to a toxin comprising a modified light chain of a botulinum toxin type E, wherein the modified light chain comprises amino acid sequence PFVNKQFN (SEQ ID NO: 120) at the N-terminus, and amino acid sequence xExxxLL (SEQ ID NO: 112) at the C-terminus, wherein x is any amino acid.
    Type: Grant
    Filed: January 8, 2010
    Date of Patent: August 30, 2011
    Assignee: Allergan, Inc.
    Inventors: Ester Fernandez-Salas, Lance E. Steward, Todd Herrington, K. Roger Aoki
  • POST-TRANSLATIONAL MODIFICATIONS AND CLOSTRIDIAL NEUROTOXINS
    Publication number: 20110046356
    Abstract: The present invention discloses modified neurotoxins with altered biological persistence. In one embodiment, the modified neurotoxins are derived from Clostridial botulinum toxins. Such modified neurotoxins may be employed in treating various conditions, including but not limited to muscular disorders, hyperhidrosis, and pain.
    Type: Application
    Filed: January 17, 2007
    Publication date: February 24, 2011
    Inventors: Lance E. Steward, Ester Fernandez-Salas, Athena Spanoyannis, K. Roger Aoki, Wei-Jen Lin
  • Post-translational modifications and Clostridial neurotoxins
    Patent number: 7893202
    Abstract: The present invention discloses modified neurotoxins with altered biological persistence. In one embodiment, the modified neurotoxins are derived from Clostridial botulinum toxins. Such modified neurotoxins may be employed in treating various conditions, including but not limited to muscular disorders, hyperhidrosis, and pain.
    Type: Grant
    Filed: January 17, 2007
    Date of Patent: February 22, 2011
    Assignee: Allergan, Inc.
    Inventors: Lance E. Steward, Ester Fernandez-Salas, Athena Spanoyannis, K. Roger Aoki, Wei-Jen Lin
  • Post-translation modification and clostridial neurotoxins
    Patent number: 7888469
    Abstract: The present invention discloses modified neurotoxins with altered biological persistence. In one embodiment, the modified neurotoxins are derived from Clostridial botulinum toxins. Such modified neurotoxins may be employed in treating various conditions, including but not limited to muscular disorders, hyperhidrosis, and pain.
    Type: Grant
    Filed: January 17, 2007
    Date of Patent: February 15, 2011
    Assignee: Allergan, Inc.
    Inventors: Lance E. Steward, Ester Fernandez-Salas, Athena Spanoyannis, K. Roger Aoki, Wei-Jen Lin
  • POST-TRANSLATIONAL MODIFICATIONS AND CLOSTRIDIAL NEUROTOXINS
    Publication number: 20100273985
    Abstract: The present invention discloses modified neurotoxins with altered biological persistence. In one embodiment, the modified neurotoxins are derived from Clostridial botulinum toxins. Such modified neurotoxins may be employed in treating various conditions, including but not limited to muscular disorders, hyperhidrosis, and pain.
    Type: Application
    Filed: January 17, 2007
    Publication date: October 28, 2010
    Inventors: Lance E. Steward, Ester Fernandez-Salas, Athena Spanoyannis, K. Roger Aoki, Wei-Jen Lin
  • POST-TRANSLATIONAL MODIFICATION AND CLOSTRIDIAL NEUROTOXINS
    Publication number: 20100273986
    Abstract: The present invention discloses modified neurotoxins with altered biological persistence. In one embodiment, the modified neurotoxins are derived from Clostridial botulinum toxins. Such modified neurotoxins may be employed in treating various conditions, including but not limited to muscular disorders, hyperhidrosis, and pain.
    Type: Application
    Filed: January 17, 2007
    Publication date: October 28, 2010
    Inventors: Lance E. Steward, Ester Fernandez-Salas, Athena Spanoyannis, K. Roger Aoki, Wei-Jen Lin
  • Chimera Botulinum Toxin Type E
    Publication number: 20100160609
    Abstract: The present invention relates to a toxin comprising a modified light chain of a botulinum toxin type E, wherein the modified light chain comprises amino acid sequence PFVNKQFN (SEQ ID NO: 120) at the N-terminus, and amino acid sequence xDxxxLL (SEQ ID NO: 111) at the C-terminus, wherein x is any amino acid.
    Type: Application
    Filed: January 8, 2010
    Publication date: June 24, 2010
    Inventors: Ester Fernandez-Salas, Lance E. Steward, Todd Herrington, K. Roger Aoki
  • CHIMERA BOTULINUM TOXIN TYPE E
    Publication number: 20100121042
    Abstract: The present invention relates to a toxin comprising a modified light chain of a botulinum toxin type E, wherein the modified light chain comprises amino acid sequence PFVNKQFN (SEQ ID NO: 120) at the N-terminus, and amino acid sequence xExxxLL (SEQ ID NO: 112) at the C-terminus, wherein x is any amino acid.
    Type: Application
    Filed: January 8, 2010
    Publication date: May 13, 2010
    Inventors: Ester Fernandez-Salas, Lance E. Steward, Todd Herrington, K. Roger Aoki
  • Chimera botulinum toxin type E
    Patent number: 7691983
    Abstract: The present invention relates to a toxin comprising a modified light chain of a botulinum toxin type E, wherein the modified light chain comprises amino acid sequence PFVNKQFN (SEQ ID NO: 120) at the N-terminus, and amino acid sequence xExxxLL (SEQ ID NO: 112) at the C-terminus, wherein x is any amino acid.
    Type: Grant
    Filed: January 14, 2005
    Date of Patent: April 6, 2010
    Assignee: Allergan, Inc.
    Inventors: Ester Fernandez-Salas, Lance E. Steward, Todd Herrington, K. Roger Aoki
  • TREATMENT OF PAIN
    Publication number: 20100034802
    Abstract: Use of a therapeutic molecule, for the treatment of specific pain conditions, wherein the therapeutic molecule is a single chain, polypeptide fusion protein, comprising: a non-cytotoxic protease, or a fragment thereof, which protease or protease fragment is capable of cleaving a protein of the exocytic fusion apparatus of a nociceptive sensory afferent; a Targeting Moiety that is capable of binding to a Binding Site on the nociceptive sensory afferent, which Binding Site is capable of undergoing endocytosis to be incorporated into an endosome within the nociceptive sensory afferent; a protease cleavage site at which site the fusion protein is cleavable by a protease, wherein the protease cleavage site is located between the non-cytotoxic protease or fragment thereof and the Targeting Moiety; and a translocation domain that is capable of translocating the protease or protease fragment from within an endosome, across the endosomal membrane and into the cytosol of the nociceptive sensory afferent.
    Type: Application
    Filed: June 1, 2007
    Publication date: February 11, 2010
    Applicants: SYNTAXIN LIMITED, ALLERGAN, INC.
    Inventors: Keith Foster, John Chaddock, Philip Marks, Patrick Stancombe, K. Roger Aoki, Joseph Francis, Lance Steward
  • Use of the neurotoxic component of a botulinum toxin for treating arthritis
    Publication number: 20090318360
    Abstract: A method and composition for treating a patient suffering from a disease, disorder or condition and associated pain include the administration to the patient of a therapeutically effective amount of a neurotoxin selected from a group consisting of Botulinum toxin types A, B, C, D, E, F and G.
    Type: Application
    Filed: August 28, 2009
    Publication date: December 24, 2009
    Applicant: ALLERGAN, INC.
    Inventors: K. Roger AOKI, Michael W. Grayston, Steven R. Carlson, Judith M. Leon
  • TREATMENT OF POST-STROKE MUSCLE PAIN
    Publication number: 20090123498
    Abstract: A method and composition for treating a patient suffering from a disease, disorder or condition and associated pain include the administration to the patient of a therapeutically effective amount of a neurotoxin selected from a group consisting of Botulinum toxin types A, B, C, D, E, F and G.
    Type: Application
    Filed: March 13, 2008
    Publication date: May 14, 2009
    Applicant: ALLERGAN, INC
    Inventors: K. Roger Aoki, Michael W. Grayston, Steven R. Carlson, Judith M. Leon
  • Methods for treating myofascial pain
    Patent number: 7501130
    Abstract: A method and composition for treating a patient suffering from a disease, disorder or condition and associated pain include the administration to the patient of a therapeutically effective amount of a neurotoxin selected from a group consisting of Botulinum toxin types A, B, C, D, E, F and G.
    Type: Grant
    Filed: April 13, 2006
    Date of Patent: March 10, 2009
    Assignee: Allergan, Inc.
    Inventors: K. Roger Aoki, Michael W. Grayston, Steven R. Carlson, Judith M. Leon